The exact cause of CIDP is not known, but it is thought to be an autoimmune disease in which the immune system mistakenly damages your nerves. This weakens your muscles and affects how they work.

Doctors usually tailor a treatment plan for CIDP based on a person’s symptoms, disease progression, lifestyle, and preferences. Not every treatment is appropriate for every person living with CIDP.

CIDP can be challenging to diagnose. Its presenting symptoms may be similar to other conditions affecting the nervous system, which include motor neuron disease, diabetic polyneuropathy ...

In 2024, the Food and Drug Administration (FDA) approved Vyvgart Hytrulo, a new effective treatment for CIDP in adults. Vyvgart Hytrulo works by reducing the level of pathogenic (disease-causing ...

Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase) is the first drug in the FcRn blocker class to treat CIDP, a rare autoimmune disease of the peripheral nervous system that causes fatigue ...

CFO updates stated that Roivant ended the quarter with $5.2 billion in cash and marketable securities, including $500 million authorized for additional share buybacks and $1 billion in stock ...

Albert Fiori was diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy or CIDP, a rare autoimmune disease that affects his eye, one arm and one leg. But he is not letting that stop him from ...

While still robust, CSL half-year results last Weds revealed impact of an “alarming” fall off in 'flu vax rates, especially ...

Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, has announced a collaboration with ...

Immunovant anticipates initiating clinical trials evaluating IMVT-1402 in a total of ten indications by March 31, 2026. Neurology Program: ...

Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.

Stephanie Lee Griffin; Chief Operating Officer; Roivant Sciences Ltd. Matt Gline; Chief Executive Officer, Director; Roivant Sciences Ltd. Dave Risinger; Analyst; Le ...